Moreover, both the epigenetic and transcriptional levels of ITGA5 are effective in predicting TMZ and bevacizumab resistance, revealing the novel roles of ITGA5 in predicting the treatment outcomes of glioma [49]. This evidence concerns the gene ITGA5 and central nervous system cancer.